Institutional Review Board, known as the Helsinki Committee has approved an experiment method using a breathing device to diagnose Coronavitus in under a minute in comparison to the current method which takes up to two days.
Developed by Israeli companies NextGen and Scentech Medical the new device is based on a breathing test similar to the police detection for ethanol contained in the blood. The test is expected to distinguish between thousands of gas compounds in the breath and identify the biological signs associated with the coronavirus and the disease it causes. Through a simple examination, it allows the diagnosis of the disease in a short time.
“I believe that with the company’s technology we will soon be able to identify the signature of the virus and the disease it is causing,” says Shulam Lapidot, who previously served as CEO of IDB and was recently appointed chairman of the NextGen company, “It is friendly for use anywhere, such as airports, hotels, tourist sites, soccer stadiums, etc. Our success will help the community and the economy get back to full operation and routine as quickly as possible. ”
The public company Next-Gen is using the technology of Scentech Medical, which identify volatile organic compounds. Both companies teamed up with Meir Medical Center to conduct an experiment that will allow COVID-19 exhalation testing and is expected to bring positive results in the near future and significantly reduce testing times as it is today.
According to the companies, this type of breathing examination has several advantages. For example, the test will enable patients to be identified asymptomatically, so that the virus can be detected early in the patient and enable its isolation quickly and minimize and even stop the spread of the disease.